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Abstract
Background
Some case-control studies reported that mitochondrial haplogroups could be associated
with the onset of cardiovascular diseases (CVD), but the literature regarding this topic is
limited. We aimed to investigate whether any mitochondrial haplogroup carried a higher or
lower risk of CVD in a large cohort of North American people affected by knee osteoarthritis
or at high risk for this condition.
Materials and methods
A longitudinal cohort study including individuals from the Osteoarthritis Initiative was done.
Haplogroups were assigned through a combination of sequencing and PCR-RFLP tech-
niques. All the mitochondrial haplogroups have been named following this nomenclature:
HV, JT, UK, IWX, and superHV/others. The strength of the association between mitochon-
drial haplogroups and incident CVD was evaluated through a Cox’s regression analysis,
adjusted for potential confounders, and reported as hazard ratios (HRs) with their 95% confi-
dence intervals (CIs).
Results
Overall, 3,288 Caucasian participants (56.8% women) with a mean age of 61.3±9.2 years
without CVD at baseline were included. During a median follow-up of 8 years, 322 individu-
als (= 9.8% of baseline population) developed a CVD. After adjusting for 11 potential con-
founders at baseline and taking those with the HV haplotype as reference (the most
frequent), those with JT carried a significant lower risk of CVD (HR = 0.75; 95%CI: 0.54–
0.96; p = 0.03). Participants with the J haplogroup had the lowest risk of CVD (HR = 0.71;
95%CI: 0.46–0.95; p = 0.02).
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Conclusions
The presence of JT haplogroups (particularly J) may be associated with a reduced risk of
CVD. However, this result was not based on a high level of statistical significance. Thus,
future research with larger sample size is needed to assess whether our results can be
corroborated.
Introduction
The human mitochondrial genome is a circular set of 16,569 base pairs encoding 37 genes,
which are translated into 13 proteins involved in the electron transfer chain, a process essential
for cellular function and survival [1]. Mitochondrial DNA (mtDNA) often undergoes muta-
tions, though at a much higher rate than nuclear DNA replication rate, while DNA repair
mechanisms are less efficient [1, 2]. In addition, the evolution of mtDNA occurs at a more
rapid pace compared to the average nuclear DNA, and thus mutations have accumulated
sequentially along radiating maternal lineages [3]. Mismatch can lead to single nucleotide
polymorphisms (SNPs), and clusters of these specific SNPs in the mitochondrial genome
define mitochondrial haplogroups. Not only germline mutations of the nuclear DNA can be
on the basis of the genetic susceptibility to different diseases including cancer [4, 5], but also
the biology of mtDNA may explain in part the genetic predisposition to certain pathological
processes: mutations in mtDNA, in fact, may influence propensity of subjects to several medi-
cal conditions [6–8]. Moreover, inherited mutations of mtDNA lead to several diseases in chil-
dren that mainly affect central nervous system, muscles and the heart [9].
The literature regarding mtDNA and cardiovascular disease (CVD) is increasing, but still
limited to a small number of studies, although there is emerging evidence that altered mito-
chondrial metabolism might play a role in the development of CVD [10–13]. In two interest-
ing reviews, the authors suggested that mitochondria are directly involved in the caloric
conversion to energy, thermogenic output, and oxidant production, and all these factors are
reported to be important for cardiovascular dysfunction [11, 13]. Moreover, mitochondrial-
nuclear relationships were established millions of years ago, but the factors that could interfere
with this genetic predisposition are largely unknown [11, 13]. In this sense, in animal models,
it was reported that to change mtDNA background significantly changes the susceptibility to
the pathological stress of cardiac volume overload, further reinforcing a role for mtDNA alter-
ations in cardiac function [12].
In human beings, in one case-control study involving 406 participants with early myocar-
dial infarction and 183 healthy controls, the authors found that the prevalence of two haplo-
types (H1 and U5) was higher in those with myocardial infarction versus controls [14]. On the
contrary, another case-control study, including 358 participants with ischemic cardiomyopa-
thy compared to 423 healthy controls, reported that haplogroups H and J are associated with a
significant higher and lower presence of ischemic cardiomyopathy, respectively [15]. The hap-
logroup J seems to be a protective factor also for the development of hypertrophic cardiomy-
opathy, as shown by another case-control study [16]. Finally, in a study involving 487 subjects
with coronary artery disease (CAD), haplogroup T was significantly more prevalent among
patients with CAD than among control subjects and, in diabetic patients, the presence of dia-
betic retinopathy was also significantly associated with a higher prevalence of haplogroup T
than controls [17]. However, a longitudinal study conducted among 9,254 Danish participants
followed-up for 25 years did not find any association between mitochondrial haplotypes and
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the incidence of CVD [18], indicating that more research is needed to understand whether
mitochondrial haplotypes are associated with CVD.
Given this background, we aimed to investigate whether any mitochondrial haplogroup
carried a significantly higher or lower risk of CVD in a large prospective cohort of North
American people affected by knee osteoarthritis or at high risk for this condition since OA can
increase per se the risk of CVD.[19].
Patients and methods
Data source and subjects
All subjects were recruited as part of the Osteoarthritis Initiative (OAI) study, freely available
at http://www.oai.ucsf.edu. Specific datasets for this work are: baseline and screening evalua-
tions (November 2008) (V00) and those evaluating the participants until the last evaluation
available (96 months; V10). Patients at high risk of knee osteoarthritis or having knee osteoar-
thritis were recruited from four clinical sites in the USA (Baltimore, MD; Pittsburgh, PA; Paw-
tucket, RI; and Columbus, OH) between February 2004 and May 2006.
All participants provided written informed consent. The OAI study protocol was approved
by the institutional review board of the OAI Coordinating Center, University of California at
San Francisco.
For this specific research, we have conducted the data elaboration and wrote the manu-
script, whilst the data collection and the administrative tasks were conducted by the OAI team.
Exposure
The haplogroup assignment was performed in agreement with other studies [20], i.e. a combi-
nation of sequencing and PCR-RFLP techniques. The sequencing technique consisted in the
multiplex assignment of the main 6 SNPs contributing to the generation of the most frequent
Caucasian haplogroups [21] (H, V, super HV, U, K, T, J), following the single base extension
(SBE) assay as reported in S1 Table.
All the mitochondrial haplogroups have been consequently named in accordance with this
nomenclature suggested by the OAI (http://www.oai.ucsf.edu/): H, U, K, J, T, V, SuperHV, I,
W, X or others. After that, we clustered these haplogroups following the classification sug-
gested by MITOMAP and followed by another study assessing mitochondrial haplogroups
and CVD [15, 22] into HV, JT, UK, and IWX. The analyzed haplogroups, in fact, share a com-
mon ancestor and several SNPs have been conserved during evolution. [15] The remaining
two groups (superHV/others) were clustered together. The superHV group used as polymor-
phism the following restriction fragment (m.14766C.T) and as restriction enzyme -MseI [23].
Outcomes
The main outcome of interest was the onset of CVD during the follow-up period. The presence
of CVD was recorded through self-reported information. We defined the development of
CVD as the presence of heart attack, heart failure, unclog or bypass arteries in legs, and stroke,
cerebrovascular accident, blood clot in brain, or transient ischemic attack. The presence
of CVD in the OAI was recorded, other than baseline, during the V3 (24 months), V6 (48
months) and V10 (96 months) [24].
Covariates
We identified a number of potential confounders in the relationship between mitochondrial
haplogroups and CVD. These included: (1) physical activity evaluated through the Physical
Mitochondrial haplogroups and CVD
PLOS ONE | https://doi.org/10.1371/journal.pone.0213656 March 28, 2019 3 / 10
Activity Scale for the Elderly [25]. This scale covers twelve different activities (e.g. walking,
sports, and housework) scoring from 0 to 400 and more; (2) smoking habits as “previous/cur-
rent” vs. never; (3) educational level categorized as “degree” vs. others; (4) yearly income
as< vs.� 50,000 $ or missing data; (5) co-morbidities assessed through the modified Charlson
comorbidity score, with higher scores indicating an increased severity of conditions; (6) pres-
ence of hypertension defined as systolic blood pressure values over 140 and/or diastolic over
90 mmHg [26]; (7) body mass index (BMI), recorded by a trained nurse, and (8) depressive
symptoms assessed through the Center for Epidemiological Studies Depression (CES-D) [27];
and (9) the use of non-steroidal anti-inflammatory drugs (NSAIDs).
Statistical analyses
For continuous variables, normal distributions were tested using the Kolmogorov-Smirnov
test. The data are reported as means and standard deviations (SD) for continuous measures,
and percentages for all categorical variables by mitochondrial haplogroups. For continuous
variables, differences between the means of the covariates by mitochondrial haplogroups were
calculated using an Analysis of Variance (ANOVA); chi-square test was applied for categorical
variables. Levene’s test was used to test the homoscedasticity of variances and, if its assumption
was violated, then Welch’s ANOVA was used. Post-hoc analyses were applied to compare
data. All the p-values were reported taking the haplotype HV (the most common) as reference.
The strength of the association of mitochondrial haplogroups and incident CVD was
assessed through a Cox’s regression analysis. Time to event was calculated as time to CVD
or to the last observation made not including the people with CVD at baseline. Dead partici-
pants were censored at the time of death. Incidence rate was reported as the number of people
having CVD during follow-up per 1,000 persons-year, with the 95% confidence intervals.
Factors significantly associated with CVD at follow-up in the univariate analysis (taking a p-
value<0.05 as statistically significant) were included in the model. Multi-collinearity among
covariates was assessed through variance inflation factor, with a cut-off of 2 as a reason of
exclusion. No variable was excluded due to this reason. Data of Cox’s regression analysis were
reported as hazard ratios (HRs) with 95% confidence intervals (CIs).
All analyses were performed using the SPSS 17.0 for Windows (SPSS Inc., Chicago, Illinois).
All statistical tests were two-tailed and statistical significance was assumed for a p-value <0.05.
Results
Study participants
At baseline, among 4,796 potentially eligible individuals, 313 already had a CVD, 866 subjects
did not have a mitochondrial DNA assessment and the other 126 did not have this assessment
for technical problems. Finally, 203 participants were lost at follow-up. Thus, 3,288 partici-
pants were enrolled in the current study.
Baseline analyses
The 3,288 participants included aged 61.3±9.2 (range: 45–79) years, with slightly more women
(= 56.8%). All the participants included were Caucasians.
The baseline characteristics of the participants by mitochondrial haplogroups are reported
in Table 1. The HV group was the most frequent haplotype (n = 1,497) and was used as the ref-
erence in all the elaborations. Compared to the HV haplogroup, no differences emerged in
terms of age, sex, BMI, NSAIDs use, hypertension or diabetes across the other groups. On the
contrary, the participants in the superHV/others haplogroup (n = 184) reported a significantly
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lower PASE score (p = 0.03) indicating a lower physical activity level and a lower education
level (p = 0.02). Finally, the IWX haplogroup (n = 141) reported a higher prevalence of people
having a low yearly income (p = 0.001) and a significant higher number of comorbidities
(p = 0.04), when compared to the HV haplogroup.
Association between mitochondrial haplogroups and CVD
After a median period of 8 years, 322 individuals (9.8% of baseline population) developed a CVD.
As shown in Table 2 and in Fig 1, the incidence of CVD was lower in people with the haplo-
type JT (11; 95%CI: 8–14 per 1,000 persons-year) and Others/superHV haplogroups (10; 95%
CI: 6–17 per 1,000 persons-year) compared to the reference group, HV (14; 95%CI: 12–16 per
1,000 persons-year).
Using a Cox’s regression analysis adjusted for eleven potential confounders and taking peo-
ple with the HV haplotype as reference, the haplogroups JT carried a significant lower risk of
incident CVD of 25% (HR = 0.75; 95%CI: 0.54–0.96; p = 0.03) (Table 2).
In a sensitivity analysis, we separated the haplogroup J from the T. After adjusting for the
same potential confounders, the haplogroup J was protective for the onset of CVD (HR = 0.71;
95%CI: 0.46–0.95; p = 0.02) in 306 participants, whilst the haplogroup T was not associated
with any significant reduction in CVD incidence (HR = 0.75; 95%CI: 0.50–1.13; p = 0.18) in
353 individuals (other details not shown).
Discussion
In this paper, in a cohort of people having knee OA or at high risk for this condition, over a fol-
low-up period of 8 years, we found that people who had an JT haplogroup carried a significantly
Table 1. Baseline characteristics by mitochondrial haplogroups.
Variable HV
(n = 1497)
JT
(n = 659)
UK
(n = 807)
IWX
(n = 141)
SuperHV/
Others (n = 184)
Age (years) 61.1 (9.2) 61.2 (9.4) 61.7 (8.9) 60.9 (9.6) 61.3 (9.4)
Females (%) 58.2 56.9 54.6 53.2 57.1
BMI (Kg/m2) 28.1 (4.6) 28.1 (4.7) 28.0 (4.7) 28.2 (4.7) 28.0 (4.3)
PASE (points) 166.5 (82.2) 163.9 (78.0) 165.7 (80.2) 174.0 (78.3) 146.4 (82.2) �
Smoking (%) 45.1 47.2 45.2 46.8 45.9
Degree (%) 33.5 32.8 35.9 37.9 28.8 �
Yearly income (<50,000 $) 29.9 29.6 30.1 41.1 �� 35.9
Medical conditions
NSAIDs use (%) 36.7 36.7 41.1 37.9 36.6
Hypertension (%) 18.6 20.5 16.0 19.1 16.3
Diabetes (%) 5.2 4.0 4.4 8.0 6.1
Charlson co-morbidity score 0.2 (0.7) 0.2 (0.6) 0.2 (0.6) 0.4 (0.9) � 0.4 (1.0)
CES-D (points) 6.1 (6.6) 5.8 (6.1) 5.8 (6.1) 6.3 (6.7) 6.3 (6.7)
Notes:
In all the comparisons, the group HV was taken as reference.
��: p<0.001
�: p<0.05.
Numbers are mean values (and standard deviations) or percentages, as appropriate.
Abbreviations: BMI: body mass index; CES-D: Center for Epidemiological Studies Depression; NSAIDs: non-steroidal anti-inflammatory drugs; PASE: physical activity
scale for the elderly.
https://doi.org/10.1371/journal.pone.0213656.t001
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lower risk of CVD of 25%, compared to the most frequent haplotypes (HV). This finding
remained significant after multivariable adjustment for several potential confounders assessed
at baseline.
It is noteworthy that at baseline, participants with the JT haplogroup did not have any sig-
nificant difference in potential CVD risk factors, including obesity, presence of hypertension
or diabetes. However, after 8 years of follow-up, the JT haplogroup (and particularly the J)
Table 2. Association between mitochondrial haplogroups and incident cardiovascular disease.
Number of people at
baseline
Incidence of CVD (95% CI) per 1,000 persons-
year
Basic adjusted
HRa
(95%CI)
P value Fully adjusted HRb(95%
CI)
P value
HV 1497 14 (12–16) 1 [reference] 1 [reference]
JT 659 11 (8–14) 0.75 (0.54–0.98) 0.03 0.75 (0.54–0.96) 0.03
UK 807 15 (12–19) 0.98 (0.75–1.28) 0.89 0.99 (0.76–1.30) 0.94
IWX 141 17 (10–26) 1.18 (0.71–1.94) 0.53 1.11 (0.67–1.83) 0.70
Others/
SuperHV
184 10 (6–17) 0.75 (0.43–1.29) 0.30 0.72 (0.41–1.25) 0.24
Notes:
a Basic adjusted model includes age (as continuous) and sex.
b Fully-adjusted model included as covariates: body mass index (as continuous); education (degree vs. others); smoking habits (current and previous vs. others); yearly
income (categorized as� or < 50,000$ and missing data); presence of hypertension (yes vs. no); Charlson co-morbidity index (as continuous); Physical Activity Scale
for Elderly score (as continuous); Center for Epidemiological Studies Depression; use of non-steroidal anti-inflammatory drugs (yes vs. no).
Abbreviations: CI: confidence intervals; HR: hazard ratio.
https://doi.org/10.1371/journal.pone.0213656.t002
Fig 1. Risk of cardiovascular disease by mitochondrial haplogroups. The data are reported as hazard ratios.
https://doi.org/10.1371/journal.pone.0213656.g001
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carried a consistent reduction in CVD incidence, suggesting an important role of these haplo-
types in CVD prevention. The haplogroup J seems to be a potentially protective factor for
other disease, such as knee osteoarthritis [20, 28]. Similarly, two case-control studies reported
that people having J haplogroup reported a significantly lower prevalence of CVD compared
to the other mitochondrial haplogroups [15, 16].
Several reasons could explain our findings. It is known that haplogroup J typically has
lower oxygen consumption than other mitochondrial haplogroups, with a consequent lower
efficiency in the electronic respiratory chain and low reactive oxygen species production [29,
30]. Thus, participants with a mitochondrial haplogroup J undergo less mitochondrial oxida-
tive damage than other haplogroups, leading to less consumption of oxygen by the heart [31].
Since oxidative stress and inflammation [32] are two key pathways in the development of ath-
erosclerosis, we can argue that this haplotype may carry a lower risk of CVD in our population.
Moreover, some mitochondrial haplogroups have also been associated with longevity. Again,
the haplogroup J was overrepresented in Finnish centenarians [33], suggesting that this hap-
logroup confers an important protection for several medical conditions in human beings.
However, we should note that a large prospective study did not find any association
between J haplogroup and the risk of ischemic CVD or mortality [18]. Contrary to the findings
of case-control studies [15, 16], in this prospective study mitochondrial haplogroups were not
associated with any significant reduction in CVD incidence. We can hypothesize that adjust-
ment for multiple covariates and the use of the Bonferroni’s correction in the analyses of this
cohort study nullified the association between mitochondrial haplogroups and CVD, in con-
trast to case-control which did not use these approaches [18]. In this regard, larger cohorts are
needed to understand the possible associations between mtDNA haplogroups and medical
conditions [34]. Other studies reported that other haplogroups confer a protection for ische-
mic transient or definitive cerebrovascular diseases, but not against myocardial infarction [35].
Thus, future longitudinal research is needed to fully understand the role of the mitochondrial
haplogroups in the development of CVD.
The findings of our study should be interpreted within its limitations. First, the presence of
CVD was assessed through self-reported information and this could have biased our results
towards the null due to misclassifcation, although one would anticipate that this would have
affected the results similarly across mitochondrial haplogroups. Second, we did not assess the
role of medications for the prevention/treatment of CVD. Third, data were only available of
mitochondrial haplogroups among Caucasians and the results do not extend beyond this eth-
nicity. On the contrary, increasing research is showing the importance of mtDNA in predict-
ing chronic diseases in Africans [36, 37] and consequently, future research is needed to
understand the role of mtDNA in these ethnicities. Finally, the OAI included only people with
or at high risk of knee osteoarthritis and so it could be not fully representative of the general
population. Thus, future longitudinal research in general population is required to address
these inconsistencies and inadequacies. Finally, we did not use P-values lower than 0.05 to
denote statistical significance as methods such as the Bonferroni correction have been criti-
cized for reasons such as high risk for type II errors, and the lack of consensus on how many
comparisons warrants this correction [38]. However, it is worth noting that with the applica-
tion of the strict Bonferroni correction, our main findings will become non-significant.
Among the strengths of our work, we can emphasize the study design (longitudinal vs. the
other case-control studies), the large cohort included at baseline and the long-follow-up
period. These last factors seem to be essential since, very large cohorts are required to detect
significant associations with human medical diseases.[34].
In conclusion, in our study, we found that mitochondrial haplogroups JT may carry a sig-
nificant lower risk of CVD compared to the most frequent haplogroups, HV. However, it is
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worth noting that this result was not based on a high level of statistical significance and that
with the use of lower P-values to denote statistical significance (e.g., Bonferroni correction),
this result is no longer significant. This indicates that our study finding is weak in terms of sta-
tistical credibility and that other research with larger populations is needed. Since sequencing
of the complete mtDNA genome is now readily available, in the coming era of personalized
medicine, these types of genetic discoveries should be integrated into clinical practice for tai-
lored therapeutic intervention strategies. [39].
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